Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Fibrosis

ClinicalTrials.gov lists 3,605 trials for Fibrosis or a narrower condition beneath it.

MeSH D005355 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 213 Phase 1/2 Phase 1/2 118 Phase 2 Phase 2 423 Phase 2/3 Phase 2/3 75 Phase 3 Phase 3 272 Phase 4 Phase 4 273 Not applicable Not applicable 1,081 Observational Observational 1,145 Phase 1 Phase 1 213 Phase 1/2 Phase 1/2 118 Phase 2 Phase 2 423 Phase 2/3 Phase 2/3 75 Phase 3 Phase 3 272 Phase 4 Phase 4 273 Not applicable Not applicable 1,081 Observational Observational 1,145

Trials per phase

2 more sections with rows

1,265 of the 3,605 trials are tagged with Fibrosis itself; the rest are tagged with a narrower condition beneath it.

Get the Fibrosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Fibrosis trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 245

1990: 1 trials (Phase 1 1) 1993: 2 trials (Observational 1, Phase 3 1) 1994: 4 trials (Not applicable 1, Phase 3 2, Phase 2 1) 1995: 6 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 2 2) 1996: 3 trials (Observational 2, Phase 3 1) 1997: 7 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 2, Phase 1 1) 1998: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 1/2 1) 1999: 7 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1) 2000: 14 trials (Observational 2, Not applicable 1, Phase 4 3, Phase 3 6, Phase 2 2) 2001: 23 trials (Observational 6, Not applicable 4, Phase 4 2, Phase 3 1, Phase 2 8, Phase 1/2 1, Phase 1 1) 2002: 22 trials (Observational 2, Not applicable 1, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 4, Phase 1/2 4) 2003: 44 trials (Observational 6, Not applicable 4, Phase 4 7, Phase 3 9, Phase 2/3 4, Phase 2 10, Phase 1/2 3, Phase 1 1) 2004: 36 trials (Observational 5, Not applicable 2, Phase 4 6, Phase 3 4, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 4) 2005: 49 trials (Observational 9, Not applicable 11, Phase 4 5, Phase 3 4, Phase 2/3 4, Phase 2 12, Phase 1/2 3, Phase 1 1) 2006: 68 trials (Observational 17, Not applicable 10, Phase 4 9, Phase 3 14, Phase 2/3 3, Phase 2 9, Phase 1/2 1, Phase 1 5) 2007: 67 trials (Observational 12, Not applicable 16, Phase 4 8, Phase 3 6, Phase 2/3 2, Phase 2 13, Phase 1/2 8, Phase 1 2) 2008: 75 trials (Observational 20, Not applicable 14, Phase 4 11, Phase 3 8, Phase 2/3 2, Phase 2 12, Phase 1/2 3, Phase 1 5) 2009: 101 trials (Observational 20, Not applicable 25, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 17, Phase 1/2 9, Phase 1 12) 2010: 118 trials (Observational 36, Not applicable 29, Phase 4 11, Phase 3 13, Phase 2/3 4, Phase 2 14, Phase 1/2 5, Phase 1 6) 2011: 123 trials (Observational 40, Not applicable 28, Phase 4 10, Phase 3 11, Phase 2/3 4, Phase 2 19, Phase 1/2 6, Phase 1 5) 2012: 125 trials (Observational 34, Not applicable 39, Phase 4 12, Phase 3 7, Phase 2/3 1, Phase 2 18, Phase 1/2 8, Phase 1 6) 2013: 147 trials (Observational 48, Not applicable 41, Phase 4 21, Phase 3 5, Phase 2/3 3, Phase 2 20, Phase 1/2 1, Phase 1 8) 2014: 133 trials (Observational 32, Not applicable 42, Phase 4 14, Phase 3 19, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 7) 2015: 154 trials (Observational 49, Not applicable 42, Phase 4 22, Phase 3 13, Phase 2/3 3, Phase 2 10, Phase 1/2 3, Phase 1 12) 2016: 146 trials (Other 1, Observational 40, Not applicable 47, Phase 4 10, Phase 3 14, Phase 2/3 4, Phase 2 16, Phase 1/2 5, Phase 1 9) 2017: 176 trials (Observational 50, Not applicable 70, Phase 4 12, Phase 3 11, Phase 2/3 4, Phase 2 22, Phase 1/2 1, Phase 1 6) 2018: 182 trials (Observational 69, Not applicable 51, Phase 4 9, Phase 3 13, Phase 2/3 2, Phase 2 18, Phase 1/2 8, Phase 1 12) 2019: 186 trials (Observational 72, Not applicable 63, Phase 4 7, Phase 3 9, Phase 2/3 3, Phase 2 18, Phase 1/2 4, Phase 1 10) 2020: 194 trials (Observational 69, Not applicable 71, Phase 4 13, Phase 3 8, Phase 2/3 3, Phase 2 15, Phase 1/2 6, Phase 1 9) 2021: 245 trials (Observational 79, Not applicable 79, Phase 4 19, Phase 3 11, Phase 2/3 3, Phase 2 24, Phase 1/2 8, Phase 1 22) 2022: 217 trials (Observational 75, Not applicable 77, Phase 4 8, Phase 3 8, Phase 2/3 9, Phase 2 20, Phase 1/2 7, Phase 1 13) 2023: 236 trials (Observational 91, Not applicable 77, Phase 4 11, Phase 3 15, Phase 2/3 5, Phase 2 19, Phase 1/2 3, Phase 1 15) 2024: 229 trials (Observational 84, Not applicable 73, Phase 4 13, Phase 3 11, Phase 2/3 3, Phase 2 23, Phase 1/2 7, Phase 1 15) 2025: 217 trials (Observational 78, Not applicable 79, Phase 4 9, Phase 3 5, Phase 2/3 1, Phase 2 24, Phase 1/2 4, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 206
2025 217
2024 229
2023 236
2022 217
2021 245
2020 194
2019 186
2018 182
2017 176

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 230 trials starting in 2026 and about 230 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 297 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 1,898 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Fibrosis trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 213
Phase 1/2 118
Phase 2 423
Phase 2/3 75
Phase 3 272
Phase 4 273
Not applicable 1,081
Observational 1,145
Expanded access 4
Unknown 1

How many Fibrosis trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 190
Recruiting 465
Enrolling by invitation 39
Active, not recruiting 141
Available 3

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Fibrosis trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Gilead Sciences 30
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 30
Renovo 25

Which drugs are being tested for Fibrosis? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ursodeoxycholic Acid 35
Avotermin 18
Lactulose 15
Obeticholic Acid 14

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ribavirine 31
Rifaximine 29
Carvedilol CR 28
Pirfenidoneone 27
Terlipressinum 18

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Fibrosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Idiopathic pulmonary fibrosis 714 22
Pneumonia 436 63
Respiratory failure 172 38
Hepatic encephalopathy 151 24
Hepatitis C 142 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Fibrosis? (1,477)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. Oral oncology 2025 Yes
The clinical manifestations and molecular pathogenesis of radiation fibrosis. EBioMedicine 2024 Yes
Regional Distribution of Extracellular Volume Quantified by Cardiac CT in Aortic Stenosis: Insights Into Disease Mechanisms and Impact on Outcomes. Circulation. Cardiovascular imaging 2024 Yes
Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation 2024 Yes
Integrative analysis identifies molecular features of fibroblast and the significance of fibrosis on neoadjuvant chemotherapy response in breast cancer. International journal of surgery (London, England) 2024 Yes

Showing 5 of 1,477 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages